Literature DB >> 21041506

In vitro activity of ceftaroline against a broad spectrum of recent clinical anaerobic isolates.

David R Snydman1, Nilda V Jacobus, Laura A McDermott.   

Abstract

The in vitro activity of ceftaroline was compared with those of ceftriaxone, clindamycin, imipenem, metronidazole, moxifloxacin, tigecycline, and vancomycin against 514 clinical anaerobic isolates using Clinical and Laboratory Standards Institute (CLSI) standard methodology. Ceftaroline demonstrated good to excellent activity against Gram-positive anaerobic pathogens and limited activity against Gram-negative pathogens, particularly Bacteroides fragilis group isolates.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21041506      PMCID： PMC3019628          DOI： 10.1128/AAC.00868-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  In vitro activity of ceftaroline against a broad spectrum of recent clinical anaerobic isolates.

Authors:  David R Snydman; Nilda V Jacobus; Laura A McDermott
Journal:  Antimicrob Agents Chemother       Date:  2010-11-01       Impact factor: 5.191

2.  Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains.

Authors:  Helio S Sader; Thomas R Fritsche; Koné Kaniga; Yigong Ge; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

3.  National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.

Authors:  D R Snydman; N V Jacobus; L A McDermott; R Ruthazer; Y Golan; E J C Goldstein; S M Finegold; L J Harrell; D W Hecht; S G Jenkins; C Pierson; R Venezia; V Yu; J Rihs; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  2007-02-05       Impact factor: 5.191

4.  In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.

Authors:  Yigong Ge; Donald Biek; George H Talbot; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2008-07-14       Impact factor: 5.191

5.  In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.

Authors:  David R Snydman; Nilda V Jacobus; Laura A McDermott
Journal:  Antimicrob Agents Chemother       Date:  2008-10-06       Impact factor: 5.191

6.  Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.

Authors:  Helio S Sader; Thomas R Fritsche; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2008-01-07       Impact factor: 5.191

7.  In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.

Authors:  D M Citron; K L Tyrrell; C V Merriam; E J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2010-01-25       Impact factor: 5.191

8.  In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.

Authors:  Shazad Mushtaq; Marina Warner; Yigong Ge; Koné Kaniga; David M Livermore
Journal:  J Antimicrob Chemother       Date:  2007-06-04       Impact factor: 5.790
  8 in total
  9 in total

Review 1.  Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.

Authors:  Thomas P Lodise; Donald E Low
Journal:  Drugs       Date:  2012-07-30       Impact factor: 9.546

2.  In vitro activity of ceftaroline against a broad spectrum of recent clinical anaerobic isolates.

Authors:  David R Snydman; Nilda V Jacobus; Laura A McDermott
Journal:  Antimicrob Agents Chemother       Date:  2010-11-01       Impact factor: 5.191

Review 3.  Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia.

Authors:  James E Frampton
Journal:  Drugs       Date:  2013-07       Impact factor: 9.546

Review 4.  The changing epidemiology of Clostridium difficile infections.

Authors:  J Freeman; M P Bauer; S D Baines; J Corver; W N Fawley; B Goorhuis; E J Kuijper; M H Wilcox
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

Review 5.  Ceftaroline Fosamil: A Review in Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2016-11       Impact factor: 9.546

6.  Critical appraisal of ceftaroline in the management of community-acquired bacterial pneumonia and skin infections.

Authors:  Julian J Goodman; Stanley I Martin
Journal:  Ther Clin Risk Manag       Date:  2012-03-26       Impact factor: 2.423

7.  Ceftaroline fosamil: a brief clinical review.

Authors:  Debbie-Ann T Shirley; Emily L Heil; J Kristie Johnson
Journal:  Infect Dis Ther       Date:  2013-08-08

Review 8.  Ceftaroline Fosamil for Treatment of Pediatric Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia.

Authors:  Susanna Esposito; Timothy J Carrothers; Todd Riccobene; Gregory G Stone; Michal Kantecki
Journal:  Paediatr Drugs       Date:  2021-08-31       Impact factor: 3.022

Review 9.  Role of cephalosporins in the era of Clostridium difficile infection.

Authors:  Mark H Wilcox; James D Chalmers; Carl E Nord; Jane Freeman; Emilio Bouza
Journal:  J Antimicrob Chemother       Date:  2016-09-22       Impact factor: 5.790
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.